GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19034052 | Liver | Cirrhotic | protein localization to nuclear body | 11/4634 | 12/18723 | 1.96e-06 | 3.65e-05 | 11 |
GO:19048672 | Liver | Cirrhotic | protein localization to Cajal body | 11/4634 | 12/18723 | 1.96e-06 | 3.65e-05 | 11 |
GO:19901733 | Liver | Cirrhotic | protein localization to nucleoplasm | 12/4634 | 14/18723 | 2.84e-06 | 5.08e-05 | 12 |
GO:00073463 | Liver | Cirrhotic | regulation of mitotic cell cycle | 154/4634 | 457/18723 | 8.73e-06 | 1.29e-04 | 154 |
GO:00511006 | Liver | Cirrhotic | negative regulation of binding | 63/4634 | 162/18723 | 4.54e-05 | 5.31e-04 | 63 |
GO:00459313 | Liver | Cirrhotic | positive regulation of mitotic cell cycle | 49/4634 | 121/18723 | 9.47e-05 | 1.01e-03 | 49 |
GO:00447721 | Liver | Cirrhotic | mitotic cell cycle phase transition | 139/4634 | 424/18723 | 1.02e-04 | 1.06e-03 | 139 |
GO:1901990 | Liver | Cirrhotic | regulation of mitotic cell cycle phase transition | 100/4634 | 299/18723 | 4.13e-04 | 3.41e-03 | 100 |
GO:2000045 | Liver | Cirrhotic | regulation of G1/S transition of mitotic cell cycle | 51/4634 | 142/18723 | 1.91e-03 | 1.20e-02 | 51 |
GO:00000821 | Liver | Cirrhotic | G1/S transition of mitotic cell cycle | 72/4634 | 214/18723 | 2.07e-03 | 1.28e-02 | 72 |
GO:00448431 | Liver | Cirrhotic | cell cycle G1/S phase transition | 77/4634 | 241/18723 | 6.68e-03 | 3.30e-02 | 77 |
GO:00457874 | Liver | Cirrhotic | positive regulation of cell cycle | 97/4634 | 313/18723 | 6.88e-03 | 3.38e-02 | 97 |
GO:1901992 | Liver | Cirrhotic | positive regulation of mitotic cell cycle phase transition | 34/4634 | 93/18723 | 7.36e-03 | 3.52e-02 | 34 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:190382922 | Liver | HCC | positive regulation of cellular protein localization | 199/7958 | 276/18723 | 1.15e-23 | 2.62e-21 | 199 |
GO:003450421 | Liver | HCC | protein localization to nucleus | 194/7958 | 290/18723 | 2.84e-17 | 2.85e-15 | 194 |
GO:005109822 | Liver | HCC | regulation of binding | 225/7958 | 363/18723 | 3.78e-14 | 2.37e-12 | 225 |
GO:190018212 | Liver | HCC | positive regulation of protein localization to nucleus | 67/7958 | 87/18723 | 5.43e-11 | 2.00e-09 | 67 |
GO:190018012 | Liver | HCC | regulation of protein localization to nucleus | 95/7958 | 136/18723 | 9.26e-11 | 3.26e-09 | 95 |
GO:00447722 | Liver | HCC | mitotic cell cycle phase transition | 240/7958 | 424/18723 | 2.47e-09 | 6.84e-08 | 240 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MEPCE | SNV | Missense_Mutation | rs754062405 | c.536N>G | p.Ser179Cys | p.S179C | Q7L2J0 | protein_coding | tolerated(0.11) | benign(0.417) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MEPCE | SNV | Missense_Mutation | | c.1313N>C | p.Lys438Thr | p.K438T | Q7L2J0 | protein_coding | deleterious(0.03) | benign(0.11) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MEPCE | SNV | Missense_Mutation | | c.1933N>C | p.Glu645Gln | p.E645Q | Q7L2J0 | protein_coding | tolerated(0.1) | possibly_damaging(0.659) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD |
MEPCE | SNV | Missense_Mutation | novel | c.1087N>T | p.Arg363Cys | p.R363C | Q7L2J0 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-GM-A3XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
MEPCE | SNV | Missense_Mutation | novel | c.1525G>A | p.Glu509Lys | p.E509K | Q7L2J0 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MEPCE | insertion | Frame_Shift_Ins | novel | c.1909_1910insGTTTCGGGGCCGGG | p.Tyr637CysfsTer11 | p.Y637Cfs*11 | Q7L2J0 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEPCE | insertion | Frame_Shift_Ins | novel | c.1911_1912insGTCC | p.Tyr638ValfsTer26 | p.Y638Vfs*26 | Q7L2J0 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEPCE | deletion | Frame_Shift_Del | novel | c.2037delN | p.Leu680CysfsTer19 | p.L680Cfs*19 | Q7L2J0 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MEPCE | SNV | Missense_Mutation | novel | c.1088G>A | p.Arg363His | p.R363H | Q7L2J0 | protein_coding | deleterious(0.05) | probably_damaging(0.98) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MEPCE | SNV | Missense_Mutation | novel | c.1058C>G | p.Ser353Cys | p.S353C | Q7L2J0 | protein_coding | deleterious(0.01) | benign(0.156) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |